PepGen (PEPG) Cash from Restructuring (2022 - 2025)

PepGen (PEPG) reported Cash from Restructuring of -$11000.0 for Q2 2025, down 200.0% sequentially from $11000.0 in Q1 2025.

PepGen (PEPG) Cash from Restructuring (2022 - 2025) Analysis & Trends

PepGen (PEPG) has 3 years of Cash from Restructuring data on file, last reported at -$11000.0 in Q2 2025.

  • For the quarter ending Q2 2025, Cash from Restructuring changed N/A year-over-year to -$11000.0; the trailing twelve-month figure through Sep 2025 stood at $50000.0 (up 177.78% YoY), and the FY2024 full-year result was $70000.0, changed N/A from the prior year.
  • Cash from Restructuring fell to -$11000.0 in Q2 2025, from $11000.0 in the prior quarter.
  • In the past five years, Cash from Restructuring ranged from a high of $50000.0 in Q4 2024 to a low of -$11000.0 in Q2 2025.
  • A 3-year average of $13600.0 and a median of $11000.0 in 2025 frame the typical range for Cash from Restructuring.
  • Peak annual rise in Cash from Restructuring reached 45.0% in 2025, while the deepest fall reached 45.0% in 2025.
  • Tracing PEPG's Cash from Restructuring over 3 years: stood at -$2000.0 in 2022, then surged by 2600.0% to $50000.0 in 2024, then slumped by 122.0% to -$11000.0 in 2025.
  • Business Quant data shows PEPG's Cash from Restructuring at -$11000.0 in Q2 2025, $11000.0 in Q1 2025, and $50000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 PepGen 145.09 Mn 145.09 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2025 -11,000.00
Mar 31, 2025 11,000.00
Dec 31, 2024 50,000.00
Mar 31, 2024 20,000.00
Dec 31, 2022 -2,000.00